Cytolytic Epstein-Barr Virus Reactivation Therapy for EBV-Associated Gastric Carcinoma

Cytolytic Epstein-Barr Virus Reactivation Therapy for EBV-Associated Gastric Carcinoma

Review Data

Purpose and Significance of Study: This novel study tested a CytoLytic Virus Activation (CLVA) strategy consisting of the combination epirubicin, capecitabine and cisplatin or capecitabine and cisplatin together with the histone deacetylase inhibitor valproic acid to determine whether EBV reactivation and subsequent antiviral treatment with ganciclovir could be used as virus-targeted therapy for EBV-associated gastric carcinoma. The results were evaluated in C666.1, AGS-BX1 and SNU-719 cell lines and in a mouse model. The CLVA treatment showed a more potent virus reactivation and killing of tumor cells when compared to standard chemotherapy alone, indicating possible use in future clinical studies.

 

Fit with Scope of Journal: The manuscript is of very high interest for the journal Clinical Oncology and Research.

 

The Introduction lays down the basis for taking up the present study. The Results are clearly explained and aptly supported by data. The Discussion encompasses the relevant findings from previous studies on CLVA and provides a thorough analysis of the findings and their implications.

 

o   The manuscript contains a few minor errors (already corrected in the galley proof), listed below –

 

·       “i.p.” and “s.c.” must be replaced with “IP” and “SC” respectively throughout the text.

·       In the 1st sentence of the Background in the Abstract, “as” must be replaced with “a”.

·       In the 1st sentence of Immunohistochemistry and EBER-RISH in the Materials and Methods, “deparaffinized” is misspelled.

·       In the 2nd sentence of the 2nd paragraph of Lytic induction in vitro, “In” at the beginning must be removed.

·       In the last sentence of the 3rd paragraph of Lytic induction in vitro, “recent” must be replaced with “recently”.

·       The 4th sentence of the 3rd paragraph of Discussion must be rephrased as “When GCb, ECC and GCb/Cis treatments in AGS-BX1 cells were compared together, the additive effect of VPA could not be seen except for GCb (Figure 3, no quantitative analyses was performed)”.

·       Commas and articles, e.g., “the” were missing in several places throughout the text.

Author Info

Corresponding Author
Jaap M. Middeldorp
Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands

Article Info

Article Type
Research Article
Publication history
Received: Fri 19, Jun 2020
Accepted: Fri 03, Jul 2020
Published: Fri 10, Jul 2020
Copyright
© 2023 Jaap M. Middeldorp. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.COR.2020.07.08